Format
Sort by
Items per page

Send to

Choose Destination

Links from Books

Items: 15

1.

Pharmacology of GPR55 in yeast and identification of GSK494581A as a mixed-activity glycine transporter subtype 1 inhibitor and GPR55 agonist.

Brown AJ, Daniels DA, Kassim M, Brown S, Haslam CP, Terrell VR, Brown J, Nichols PL, Staton PC, Wise A, Dowell SJ.

J Pharmacol Exp Ther. 2011 Apr;337(1):236-46. doi: 10.1124/jpet.110.172650. Epub 2011 Jan 13.

2.

The putative cannabinoid receptor GPR55 defines a novel autocrine loop in cancer cell proliferation.

Piñeiro R, Maffucci T, Falasca M.

Oncogene. 2011 Jan 13;30(2):142-52. doi: 10.1038/onc.2010.417. Epub 2010 Sep 13.

PMID:
20838378
3.

The orphan G protein-coupled receptor GPR55 promotes cancer cell proliferation via ERK.

Andradas C, Caffarel MM, Pérez-Gómez E, Salazar M, Lorente M, Velasco G, Guzmán M, Sánchez C.

Oncogene. 2011 Jan 13;30(2):245-52. doi: 10.1038/onc.2010.402. Epub 2010 Sep 6.

PMID:
20818416
4.

A role for L-alpha-lysophosphatidylinositol and GPR55 in the modulation of migration, orientation and polarization of human breast cancer cells.

Ford LA, Roelofs AJ, Anavi-Goffer S, Mowat L, Simpson DG, Irving AJ, Rogers MJ, Rajnicek AM, Ross RA.

Br J Pharmacol. 2010 Jun;160(3):762-71. doi: 10.1111/j.1476-5381.2010.00743.x.

5.

Pharmacological characterization of GPR55, a putative cannabinoid receptor.

Sharir H, Abood ME.

Pharmacol Ther. 2010 Jun;126(3):301-13. doi: 10.1016/j.pharmthera.2010.02.004. Epub 2010 Mar 16. Review.

6.

The putative cannabinoid receptor GPR55 affects osteoclast function in vitro and bone mass in vivo.

Whyte LS, Ryberg E, Sims NA, Ridge SA, Mackie K, Greasley PJ, Ross RA, Rogers MJ.

Proc Natl Acad Sci U S A. 2009 Sep 22;106(38):16511-6. doi: 10.1073/pnas.0902743106. Epub 2009 Sep 3.

7.

Atypical responsiveness of the orphan receptor GPR55 to cannabinoid ligands.

Kapur A, Zhao P, Sharir H, Bai Y, Caron MG, Barak LS, Abood ME.

J Biol Chem. 2009 Oct 23;284(43):29817-27. doi: 10.1074/jbc.M109.050187. Epub 2009 Sep 1.

8.

The putative cannabinoid receptor GPR55 plays a role in mechanical hyperalgesia associated with inflammatory and neuropathic pain.

Staton PC, Hatcher JP, Walker DJ, Morrison AD, Shapland EM, Hughes JP, Chong E, Mander PK, Green PJ, Billinton A, Fulleylove M, Lancaster HC, Smith JC, Bailey LT, Wise A, Brown AJ, Richardson JC, Chessell IP.

Pain. 2008 Sep 30;139(1):225-36. doi: 10.1016/j.pain.2008.04.006. Epub 2008 May 27.

PMID:
18502582
9.

Inhibition of N-type calcium channels by activation of GPR35, an orphan receptor, heterologously expressed in rat sympathetic neurons.

Guo J, Williams DJ, Puhl HL 3rd, Ikeda SR.

J Pharmacol Exp Ther. 2008 Jan;324(1):342-51. Epub 2007 Oct 16.

10.

Novel cannabinoid receptors.

Brown AJ.

Br J Pharmacol. 2007 Nov;152(5):567-75. Epub 2007 Oct 1. Review.

11.

The orphan receptor GPR55 is a novel cannabinoid receptor.

Ryberg E, Larsson N, Sjögren S, Hjorth S, Hermansson NO, Leonova J, Elebring T, Nilsson K, Drmota T, Greasley PJ.

Br J Pharmacol. 2007 Dec;152(7):1092-101. Epub 2007 Sep 17.

12.

The novel endocannabinoid receptor GPR55 is activated by atypical cannabinoids but does not mediate their vasodilator effects.

Johns DG, Behm DJ, Walker DJ, Ao Z, Shapland EM, Daniels DA, Riddick M, Dowell S, Staton PC, Green P, Shabon U, Bao W, Aiyar N, Yue TL, Brown AJ, Morrison AD, Douglas SA.

Br J Pharmacol. 2007 Nov;152(5):825-31. Epub 2007 Aug 20.

13.

Zaprinast, a well-known cyclic guanosine monophosphate-specific phosphodiesterase inhibitor, is an agonist for GPR35.

Taniguchi Y, Tonai-Kachi H, Shinjo K.

FEBS Lett. 2006 Sep 18;580(21):5003-8. Epub 2006 Aug 17.

14.

A beta-arrestin/green fluorescent protein biosensor for detecting G protein-coupled receptor activation.

Barak LS, Ferguson SS, Zhang J, Caron MG.

J Biol Chem. 1997 Oct 31;272(44):27497-500.

15.

Internal trafficking and surface mobility of a functionally intact beta2-adrenergic receptor-green fluorescent protein conjugate.

Barak LS, Ferguson SS, Zhang J, Martenson C, Meyer T, Caron MG.

Mol Pharmacol. 1997 Feb;51(2):177-84.

Supplemental Content

Support Center